CRISPR Stock Price History Breakdown

CRSP
 Stock
  

USD 71.74  4.11  5.42%   

As of today, the current price of CRISPR Therapeutics is  71.74 , as last reported on the 17th of August 2022, with the highest price reaching  74.88  and the lowest price hitting  71.01  during the day.
CRISPR Therapeutics appears to be very steady, given 3 months investment horizon. CRISPR Therapeutics secures Sharpe Ratio (or Efficiency) of 0.1, which signifies that the company had 0.1% of return per unit of return volatility over the last 3 months. Our approach to foreseeing the volatility of a stock is to use all available market data together with stock-specific technical indicators that cannot be diversified away. By reviewing CRISPR Therapeutics technical indicators you can today evaluate if the expected return of 0.51% is justified by implied risk. Please makes use of CRISPR Therapeutics' Risk Adjusted Performance of 0.2225, semi deviation of 4.52, and Mean Deviation of 3.92 to double-check if our risk estimates are consistent with your expectations.
  
As of 17th of August 2022, Net Income Common Stock is likely to grow to about 407.5 M. As of 17th of August 2022, Price to Book Value is likely to grow to 3.01. Also, Price to Earnings Ratio is likely to grow to 16.45. CRISPR Stock price history is provided at the adjusted basis, taking into account all of the recent filings.

Most Recent Activity

Shares Float
76.9 M
Shares Outstanding
78 M
Shares Short Prior Month
11.5 M
Earnings Share
3.76
Shares Short
11 M
Revenue Per Share
0.19

CRISPR Therapeutics August 17, 2022 Stock Price Synopsis

CRISPR Therapeutics Accumulation Distribution 73,317 
CRISPR Therapeutics Price Rate Of Daily Change 0.95 
CRISPR Therapeutics Price Action Indicator(3.26) 
CRISPR Therapeutics Price Daily Balance Of Power(1.06) 

CRISPR Therapeutics August 17, 2022 Stock Price Analysis

Share Download
When benchmark price declines in a down market, there may be an uptick in CRISPR Stock price where buyers come in believing the asset is cheap or selling overdone. The opposite is true when the market is bullish. You can use CRISPR Therapeutics intraday prices and daily technical indicators to check the level of noise trading in CRISPR Stock and then apply it to test your longer-term investment strategies against CRISPR.

CRISPR Therapeutics Stock Price History Chart

There are several ways to analyze CRISPR Stock price data. The simplest method is using a basic CRISPR candlestick price chart, which shows CRISPR Therapeutics price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.

90 Days Highest PriceJuly 19, 202283.78
90 Days Lowest PriceMay 24, 202252.38

CRISPR Stock Price History Data

The price series of CRISPR Therapeutics for the period between Thu, May 19, 2022 and Wed, Aug 17, 2022 has a statistical range of 37.24 with a coefficient of variation of 14.77. The prices are distributed with arithmetic mean of 68.71. The median price for the last 90 days is 70.6.
OpenHighLowCloseVolume
08/17/2022 73.93  74.88  71.01  71.74  1,418,594 
08/16/2022 80.11  80.46  75.35  75.85  1,082,000 
08/15/2022 78.59  80.60  77.06  80.14  855,700 
08/12/2022 77.50  80.10  76.39  78.66  898,205 
08/11/2022 80.00  83.79  77.27  77.46  1,451,900 
08/10/2022 77.75  79.27  75.14  78.87  1,104,400 
08/09/2022 78.55  78.57  74.57  75.13  1,579,900 
08/08/2022 81.00  84.10  80.16  81.39  1,535,900 
08/05/2022 76.44  81.90  75.14  81.40  1,643,500 
08/04/2022 79.51  80.50  76.02  78.91  1,459,800 
08/03/2022 77.92  83.05  77.72  78.58  1,566,500 
08/02/2022 73.38  77.26  73.29  76.34  935,000 
08/01/2022 74.00  76.76  72.90  74.01  958,100 
07/29/2022 75.00  75.74  73.03  75.00  1,013,500 
07/28/2022 79.26  80.91  74.32  75.90  1,202,000 
07/27/2022 77.76  79.21  75.13  78.93  845,500 
07/26/2022 76.27  79.86  75.15  77.12  1,237,500 
07/25/2022 75.23  76.88  72.71  76.50  1,187,600 
07/22/2022 80.56  80.69  75.10  75.82  1,530,700 
07/21/2022 82.16  82.34  78.52  79.95  1,465,000 
07/20/2022 83.55  86.95  81.56  82.34  2,214,400 
07/19/2022 80.91  83.95  78.60  83.78  1,305,500 
07/18/2022 84.56  85.86  79.36  79.36  1,720,600 
07/15/2022 81.91  83.39  77.82  83.39  1,541,200 
07/14/2022 80.62  83.50  80.02  81.91  2,131,100 
07/13/2022 75.56  82.68  75.04  80.70  3,271,000 
07/12/2022 74.71  79.78  72.41  79.05  2,552,600 
07/11/2022 76.28  77.35  73.26  73.71  1,898,900 
07/08/2022 76.51  79.15  75.65  76.70  1,726,800 
07/07/2022 72.06  79.27  72.00  78.20  2,789,200 
07/06/2022 70.70  76.99  70.65  72.70  4,849,800 
07/05/2022 63.39  71.64  62.04  70.60  3,039,600 
07/01/2022 61.11  64.00  60.41  63.79  947,600 
06/30/2022 61.92  63.20  60.67  60.77  1,376,600 
06/29/2022 62.76  63.90  60.99  63.00  1,714,800 
06/28/2022 66.48  67.70  62.56  63.28  1,556,100 
06/27/2022 67.06  69.42  63.62  66.90  2,494,100 
06/24/2022 66.57  67.16  61.06  66.96  2,951,800 
06/23/2022 59.16  65.95  57.78  65.15  3,407,500 
06/22/2022 63.01  63.23  56.34  59.94  5,836,800 
06/21/2022 71.01  75.24  59.82  64.67  7,447,200 
06/17/2022 66.45  72.28  66.25  70.00  5,957,500 
06/16/2022 59.99  65.52  59.72  64.64  2,406,600 
06/15/2022 58.90  63.08  58.90  62.66  2,082,300 
06/14/2022 55.74  58.13  53.52  58.11  1,531,600 
06/13/2022 59.26  59.71  53.36  55.27  3,761,200 
06/10/2022 67.83  69.29  63.11  63.76  1,887,000 
06/09/2022 72.84  75.42  71.69  71.70  1,305,700 
06/08/2022 68.87  74.59  68.44  73.83  2,577,800 
06/07/2022 63.15  69.05  63.15  69.04  1,392,500 
06/06/2022 65.70  66.39  63.38  64.22  1,219,400 
06/03/2022 59.70  65.58  59.52  64.21  1,998,000 
06/02/2022 57.53  62.20  56.85  61.00  1,552,200 
06/01/2022 58.07  59.33  56.60  57.87  1,206,800 
05/31/2022 57.69  59.42  56.42  58.05  1,460,600 
05/27/2022 56.01  58.56  54.49  58.34  1,112,400 
05/26/2022 54.67  56.72  53.89  55.23  987,800 
05/25/2022 51.76  54.94  51.55  54.55  1,101,400 
05/24/2022 53.42  53.91  51.46  52.38  1,096,500 
05/23/2022 55.94  57.25  53.96  54.71  925,100 
05/20/2022 56.65  58.08  52.73  56.34  1,339,800 

About CRISPR Therapeutics Stock history

CRISPR Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for CRISPR is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in CRISPR Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing CRISPR Therapeutics historical stock prices may prove useful in developing a viable investing in CRISPR Therapeutics
Last ReportedProjected for 2022
Weighted Average Shares75.9 M62.1 M
Weighted Average Shares Diluted80.4 M64.9 M
Issuance Purchase of Equity Shares250.9 M284.5 M
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. Its CRISPRCas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The companys lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patients hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics Quarterly Market Capitalization

4.71 Billion

CRISPR Therapeutics Stock Technical Analysis

CRISPR Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of CRISPR Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of CRISPR Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Did you try this?

Run Probability Of Bankruptcy Now

   

Probability Of Bankruptcy

Get analysis of equity chance of financial distress in the next 2 years
All  Next Launch Module

CRISPR Therapeutics Technical and Predictive Indicators

Predictive indicators are helping investors to find signals for CRISPR stock's direction in advance. Along with the technical and fundamental analysis of CRISPR Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of CRISPR to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen stock market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Continue to Trending Equities. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.9 B
Quarterly Revenue Growth YOY
-1.0
Return On Assets
-0.15
Return On Equity
-0.27
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.